Western Drug Recalls Testost CYP 200mg/mL Due to Sterility Concerns
Western Drug is recalling Testost CYP 200mg/mL SUS due to a lack of assurance of sterility. The product was distributed nationwide in eight states.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II and involves a lack of assurance of sterility, which poses a risk of serious injury or death from infection, meeting the criteria for a Severe rating.
Plain-English summary
Western Drug Inc. is recalling Testost CYP 200mg/mL SUS, a prescription medication. The recall was initiated because of a lack of assurance of sterility in the product.
The affected product consists of 2 containers and includes all lots. The medication was distributed nationwide in the United States, specifically in Arizona, California, Georgia, New Mexico, South Carolina, South Dakota, Texas, and Utah.
Consumers and healthcare providers should stop using the recalled product and contact their healthcare provider or pharmacist for further instructions. The recall is classified as FDA Class II.
The recalled product
- Product
- Testost CYP 200mg/mL SUS, Rx, Western Drug Inc. 106 E. Main Street, Springerville, Arizona 85938
- Manufacturer
- Western Drug
- Category
- Drug — Prescription Medication
- Affected units
- 2
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- all lots
Distribution
Part of a larger recall action
This product is one of 91 recalled by Western Drug under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 91 products in this recall →Related recalls
Same manufacturer · Western Drug
See all →- SevereWestern Drug Recalls Sodium Hydroxide 10% Injection Due to Sterility Concerns
FDA (Drugs) · 2015-12-09
- SevereWestern Drug Recalls Methylcobalamin Injection Due to Sterility Concerns
FDA (Drugs) · 2015-12-09
- SevereWestern Drug Recalls Benadryl Injection Due to Sterility Concerns
FDA (Drugs) · 2015-12-09
- SevereWestern Drug Recalls PZI 40 Insulin Due to Sterility Concerns
FDA (Drugs) · 2015-12-09
- SevereWestern Drug Recalls Ketorolac Injection Due to Sterility Concerns
FDA (Drugs) · 2015-12-09
Same hazard · sterility
See all →- SevereHouston Rx LLC Recalls Tirzepatide/Niacinamide Vials Due to Sterility Concerns
FDA (Drugs) · 2026-10-21
- SevereFDA Recalls Tri-MIX Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- HighFDA recalls injectable compounded mixture in single-use syringes
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tri-MIX Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tirzepatide Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
Similar recalls
- SevereMedaus Recalls Testosterone Cyp 200 mg/mL Due to Sterility Concerns
FDA (Drugs) · 2013-09-25
- SeverePerry Drug Recalls Testosterone Cyp Syringes Due to Sterility Concerns
FDA (Drugs) · 2014-12-03
- SevereTEST CYP 200MG/ML injection recalled due to sterility assurance concerns
FDA (Drugs) · 2021-11-03
- SevereNorthwest Compounding Pharmacy Recalls Testosteron Cypionate Liquid Due to Sterility Concerns
FDA (Drugs) · 2019-01-09
- SevereMedaus Recalls Testosterone Cypionate Vials Due to Sterility Concerns
FDA (Drugs) · 2016-07-20
- HighInjectable testosterone product recalled for sterility assurance defect
FDA (Drugs) · 2022-09-21